Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Infertility Trial Endpoints: Committee Says Don’t Count Your Eggs

Executive Summary

Infertility drug trials should use clinical pregnancy as a primary endpoint, as defined by the presence of a fetal heart beat and gestational sac, FDA's Reproductive Health Drugs Advisory Committee members agreed Sept. 29

You may also be interested in...



Product Withdrawal Can Be As Hard As Approval: Luveris' 4-Year Journey Ends

EMD Serono had not marketed the infertility treatment in US since 2012, when it first asked FDA to withdraw application; company was unable to complete confirmatory trial required under accelerated approval.

Serono Infertility Treatment Luveris Clears FDA

Serono will study the effect of the recombinant luteinizing hormone infertility treatment Luveris on time to clinical pregnancy as a Phase IV commitment

Serono Infertility Treatment Luveris Clears FDA

Serono will study the effect of the recombinant luteinizing hormone infertility treatment Luveris on time to clinical pregnancy as a Phase IV commitment

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel